All News
STAT+: Court ruling opens door to FDA action against Ozempic compounders
A court ruling has opened the door to FDA action against Ozempic compounders, a major win for Novo Nordisk.
Read MoreWomen Happier With Vaginal Tape Slings for Stress Urinary Incontinence
(MedPage Today) -- Women with stress urinary incontinence reported more satisfaction with long-term outcomes when treated with a tension-free vaginal tape (TVT) procedure than bulking therapy with tr
Read MoreSS Innovations International makes NASDAQ Debut
SS Innovations International reported revenues reaching $20.6 million for the year ending December 31, 2024, rising by 40.
Read MoreBPL Medical Technologies announces leadership changes
Sunil Khurana is promoted to Executive Chairman, while Dr Shravan Subramanyam assumes the role of MD, and Guruswamy K takes over as the CEO
Read MoreAHPI Delhi Chapter holds executive committee meeting for 2024–25
Dr Mradul Kaushik will now serve as the President, while Mahipal Bhanot and Dr Ajay Bedi assume the role of Vice President
Read MoreGlobalData highlights implications of US tariffs on IVD market
According to GlobalData, these tariffs are expected to impact all 510(k)-approved medical devices manufactured outside of the US
Read MoreWhat ‘Fertilization President’ Trump Can Learn From State Efforts To Expand IVF Access
State-level efforts to regulate fertility coverage reveal the gauntlet of budgetary and political hurdles such initiatives face — obstacles that have led to millions of people being left out even wh
Read MoreMoms in Crisis, Jobs Lost: The Human Cost of Trump’s Addiction Funding Cuts
In many cases, the money flowed to addiction recovery programs that help rebuild lives by driving people to medical appointments and court hearings, crafting résumés and training them for new jobs,
Read MoreSTAT+: Struggling lobbyists, panicked clients: D.C. comes to grips with Trump’s second term
Trump's second term is playing out a lot differently than health care companies and their lobbyists hoped for.
Read More